1. Others
  2. Others
  3. Ibrolipim

Ibrolipim (Synonyms: NO-1886)

Cat. No.: HY-117549 Purity: 99.19%
Handling Instructions

Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects.

For research use only. We do not sell to patients.

Ibrolipim Chemical Structure

Ibrolipim Chemical Structure

CAS No. : 133208-93-2

Size Price Stock Quantity
10 mM * 1  mL in DMSO USD 115 In-stock
Estimated Time of Arrival: December 31
5 mg USD 116 In-stock
Estimated Time of Arrival: December 31
10 mg USD 197 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects[1][2][3].

IC50 & Target

Lipoprotein lipase (LPL)[1][2][3]

In Vitro

Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at translational levels in a dose-dependent and time-dependent manner [1].
Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner [1].
Ibrolipim 5 and 50 μmol/L significantly increases cholesterol efflux from THP-1 macrophage-derived foam cells to apoA-I or HDL. LXRα is also upregulated by the Ibrolipim treatment. LXRα small interfering RNA completely abolishes the promotion effect that is induced by Ibrolipim[1].

Western Blot Analysis[1]

Cell Line: THP-1 macrophage-derived foam cells
Concentration: 0.5 μM, 5 μM, 10 μM
Incubation Time: 0 hour, 6 hours, 12 hours, 24 hours
Result: Increased ABCA1 and ABCG1 translational levels in a dose-dependent and time-dependent manner.

RT-PCR[1]

Cell Line: THP-1 macrophage-derived foam cells
Concentration: 0.5 μM, 5 μM, 10 μM
Incubation Time: 0 hour, 6 hours, 12 hours, 24 hours
Result: Increased ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner.
In Vivo

Ibrolipim (NO-1886; 100 mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue[2].

Animal Model: Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment[2]
Dosage: 100 mg/kg
Administration: Oral administration; daily; for 8 weeks
Result: Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy.
Molecular Weight

451.25

Formula

C₁₉H₂₀BrN₂O₄P

CAS No.

133208-93-2

SMILES

BrC1=CC(C#N)=C(C=C1)NC(C2=CC=C(C=C2)CP(OCC)(OCC)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (277.01 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2161 mL 11.0803 mL 22.1607 mL
5 mM 0.4432 mL 2.2161 mL 4.4321 mL
10 mM 0.2216 mL 1.1080 mL 2.2161 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

*All of the co-solvents are provided by MCE.
References

Purity: 99.19%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

IbrolipimNO-1886NO1886NO 1886OthersAntihyperlipidemiclipoproteinlipaseLDL-CHDL-CfattyacidUCP3obesityLXRαInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ibrolipim
Cat. No.:
HY-117549
Quantity:
MCE Japan Authorized Agent: